Elevated plasma CAF22 are incompletely restored six months after COVID-19 infection in older men

Karim, Asima; Muhammad, Tahir; Iqbal, Meesha; Qaisar, Rizwan

doi:10.1016/j.exger.2022.112034

Cited by 17 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other factors include inactivity, medications, malnutrition, multimorbidity, deterioration of the antioxidant system, and a potent cytokine storm 50–54 . While the long‐term effects of COVID‐19 on muscle remain to be seen, there are indications that the adverse effects of COVID‐19 on skeletal muscle may be long‐lasting or permanent 49,55 …”

Section: Mediators Of Frailty In the Covid‐19 Pandemicmentioning

confidence: 99%

See 1 more Smart Citation

Frailty after COVID‐19: The wave after?

2023

View full text Add to dashboard Cite

The COVID‐19 pandemic poses an ongoing public health challenge, with a focus on older adults. Given the large number of older persons who have recovered from COVID‐19 and reports of long‐lasting sequelae, there is reasonable concern that the COVID‐19 pandemic may lead to a long‐term deterioration in the health of older adults, i.e., a potential “wave of frailty.” Therefore, it is critical to better understand the circumstances surrounding the development of frailty as a result of COVID‐19, as well as the underlying mechanisms and factors contributing to this development. We conducted a narrative review of the most relevant articles published on the association between COVID‐19 and frailty through January 2023. Although few studies to date have addressed the effects of COVID‐19 on the onset and progression of frailty, the available data suggest that there is indeed an increase in frailty in the elderly as a result of COVID‐19. Regarding the underlying mechanisms, a multicausal genesis can be assumed, involving both direct viral effects and indirect effects, particularly from the imposed lockdowns with devastating consequences for the elderly: decreased physical activity, altered diet, sarcopenia, fatigue, social isolation, neurological problems, inflammation, and cardiovascular morbidity are among the possible mediators. Since the COVID‐19 pandemic is leading to an increase in frailty in the elderly, there is an urgent need to raise awareness of this still little‐known problem of potentially great public health importance and to find appropriate prevention and treatment measures.

show abstract

Section: Mediators Of Frailty In the Covid‐19 Pandemicmentioning

confidence: 99%

“… 50 , 51 , 52 , 53 , 54 While the long‐term effects of COVID‐19 on muscle remain to be seen, there are indications that the adverse effects of COVID‐19 on skeletal muscle may be long‐lasting or permanent. 49 , 55 …”

Section: Mediators Of Frailty In the Covid ‐19 Pan...mentioning

confidence: 99%

Frailty after COVID‐19: The wave after?

2023

View full text Add to dashboard Cite

show abstract

“…Afterward, glutathione (GSH) and enzymes that employ GSH may detoxify oxidized lipids [37]. Furthermore, Vit E deficiency is related to ferroptosis and other studies suggest that Vit E supplementation at the high dose of 500 mg/kg may act as a treatment to inhibit ferroptosis in COVID-19 patients and decrease the damages caused by ferroptosis to multiple organs, such as lung, kidney, liver, gut, heart, and nervous system [38]. Our results show an increase in the ferroptosis in COVID-19 before of the treatment with Vit E. However, we could not validate whether ferroptosis decreased in these patients after treatment with Vit E, and therefore, more studies are required to confirm this.…”

mentioning

confidence: 99%

Preliminary Study on the Restoration of the Phospholipid Profile in Serum from Patients with COVID-19 by Treatment with Vitamin E

Soto,

Manzano-Pech,

Guarner-Lans

et al. 2024

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 is an obligatory intracellular pathogen that requires of a lipid bilayer membrane for its transport, to build its nucleocapsid envelope and to fuse with the host cell. The biological membranes are constituted by phospholipids (PLs) and vitamin E (Vit E) protects them from oxidative stress (OS). The aim of this study was to demonstrate if the treatment with Vit E restores the modified profile of the FA in PLs in serum from patients with coronavirus disease-19 (COVID-19). We evaluated Vit E, total fatty acids (TFA), fatty acid of the phospholipids (FAPL), total phospholipids (TPLs), 8-isoprostane, thromboxane B2 (TXB2), prostaglandins (PGE2 and 6-keto-PGF1α), interleukin-6 (IL-6) and C-reactive protein (CRP) in serum from 22 COVID-19 patients before and after treatment with Vit E and compared the values with those from 23 healthy subjects (HS). COVID-19 patients showed a decrease in Vit E, TPLs, FAPL and TFA in serum in comparison to HS (p≤0.01) and Vit E treatment restored their levels (p≤0.04). Likewise, there was an increase IL-6 and CRP in COVID-19 patients in comparison with HS (p≤0.001) and the treatment with Vit E decreased their levels (p≤0.001). Treatment with Vit E contributes to restore the modified profile of the PLs in the SARS-CoV-2 infection and this leads to a decrease of OS and of the inflammatory process.

show abstract